Timetable

Invited Address Free Paper Session Symposium Sponsored Symposium Opening Session Closing Session Break Poster Session

Sunday, 19 June 2011
15:00	01Registration and Welcome Refreshments Conference Hall 2
16:00	02Opening Ceremony Plenary Theatre Auditorium Prof. Graham Burrows AO KCSJ - Co-Chair on behalf of the Organizing Committee Prof Graham Burrows AO KCSJ, University of Melbourne, Australia Dr Abdul Kadir Abu Bakar - Co-Chair on behalf of the Malaysian Psychiatric Association Dr Abdul Kadir Abu Bakar, Malaysian Psychiatric Association, Malaysia Hans-Jürgen Möller - President on behalf of CINP Prof. Hans-Jürgen Möller, Ludwig-Maximilians-University München, Germany
16:30	03CINP Presidential Address Plenary Theatre Auditorium Chairperson Prof Graham Burrows AO KCSJ University of Melbourne Australia The place of antidepressants in the complex treatment of depressive patients Prof. Hans-Jürgen Möller, Ludwig-Maximilians-University München, Germany
17:15	27Building blocks of new psychiatric services: post Mental Health Act 2001 Plenary Theatre Auditorium Chairperson Prof Graham Burrows AO KCSJ University of Melbourne Australia Building blocks of new psychiatric services: post Mental Health Act 2001 Dr Abdul Kadir Abu Bakar, Malaysian Psychiatric Association, Malaysia
18:00	04Welcome Reception Conference Hall 2
19:30

Monday, 20 June 2011
08:30	05Biomarker in Psychiatric Disorders Plenary Theatre Auditorium Chairperson Prof Em Hoi Sen Yong University of Malaya Malaysia Perhipheral biomarkers for psychosis Prof Ian Everall, The University of Melbourne, Australia Novel biomarkers for schizophrenia in Malaysian population Dr Loh Han Chern, Universiti Tunku Abdul Rahman, Malaysia Separating schizophernia - what do microarrays of the CNS tell us? Dr Elizabeth Scarr, The University of Melbourne, Department of Psychiatry, Australia The search for biomarkers in psychiatric disorders: Studies of the human CNS proteome Prof Brian Dean, The Mental Health Research Institution, Australia	06Peptidergic regulation of arousal, emotional, reward and social behaviour: Implications for psychiatric disease Meeting Room 304/305 Chairperson A/Prof Andrew Gundlach Florey Neuroscience Institutes Australia Social stress and defeat, from circuits to methylation - exploring stress-induced alterations in neurobiology that drive changes in behavioural state and cognitive function in the adult rat Dr Frederick Rohan Walker, University of Newcastle, School of Biomedical Sciences and Pharmacy, Australia Orexin/dynorphin systems in control of motivated/reward behaviour Dr Gavan P McNally, The University of New South Wales, Australia Neuropeptide S system in arousal, anxiety and panic disorder A/Prof Rainer Reinscheid, University of California Irvine, United States Relaxin-3/RXFP3 networks - a newly identified ascending arousal system A/Prof Andrew L Gundlach, Florey Neuroscience Institutes, Australia
10:00	07Refreshment & Posters Conference Hall 2 Multidimensional comparison on personality of the Big Five model, impulsiveness and affect between pathological gambling and obsessive-compulsive disorder Dr Jae Yeon Hwang, Department of Brain and Cognitive Sciences – WCU program, Seoul National University, Seoul, Republic of Korea, Korea The effect of sertraline and paroxetine on cognitive function and quality of life in first episode patients with major depressive disorder Dr Jun Yao, Shanghai Tongji Hospital, China Memory retrieval and extinction of Pavlovian conditioned fear Ms Wan Yee Macy Chan, University of New South Wales, Australia Electroconvulsive seizures affect VEGF and mTORC1 Betina Elfving, Centre for Psychiatric Research, Aarhus University Hospital Risskov, Denmark The role of VTA dopamine in predictive fear learning Ms Susan S Li, University of New South Wales, Australia Chronic restraint stress changes hippocampal protein expression, branching pattern, and spine density in Wistar rats Dr Heidi K Müller, Centre for Psychiatric Research, Aarhus University Hospital, 8240 Risskov, Denmark Age Related Performance to Criterion during the Object Retrieval Task in Female Cynomolgus Macaques Mr Chan Sing Chew, Maccine Pte Ltd, Singapore Preclinical and clinical evaluation of JNJ-18038683, a selective 5-HT7 receptor antagonist, in major depressive disorder Pascal Bonaventure, Johnson & Johnson Pharmaceutical Research & Development, LLC., United States Depression, suicidal ideation and mental health service in adolescents Ms Hui-Chun Huang, Department of Medical Research, Mackay Memorial Hospital, Taiwan Effects of olanzapine on 4 cases with major depression (5 episodes) Dr Masahiro Kuniyoshi, Chikusuikai Hospital and Chikusuikai Inst. of Neuroinformation, Japan Reliability and Validity of a Chinese Version of the Patient Health Questionnaire as a Screening Instrument for Major Depressive Disorders among Adolescents in Taiwan Shen-Ing Liu, Department of Psychiatry, Mackay Memorial Hospital, Taipei, Taiwan, Taiwan Effects of ziprasidone on the QTc interval: A pooled data analysis Dr Moh-Lim Ong, Pfizer Changes in metabolic parameters in adult subjects in randomized, placebo-controlled studies of ziprasidone Dr Moh-Lim Ong, Pfizer Altered distribution of P300 component of event-related potentials in persons with Asperger’s disorder Dr Akira Iwanami, Department of Psychiatry, Showa University School of Medicine, Japan Prefrontal dysfunction in persons with Asperger’s disorder investigated with multi-channel near-infrared spectroscopy Dr Akira Iwanami, Department of Psychiatry, Showa University School of Medicine, Japan Circulating steroids are efficient predictors of schizophrenia Dr Daniela Ripova, Prague Psychiatric Center, Czech Republic Clinical and functional outcomes for patients with schizophrenia treated with olanzapine in Japan: One-year naturalistic outcomes for inpatients and outpatients Wendy Ye, Lilly Research Laboratories Japan, Eli Lilly Japan K.K., Japan Predictors of Antipsychotic Monotherapy with Olanzapine during a 1-Year Naturalistic Study of Schizophrenia Patients in Japan Yuka Tanji, Lilly Research Laboratories Japan, Eli Lilly Japan K.K., Japan Withdrawn: Synergistic interaction between prenatal immune challenge and peri-pubertal stress in the disruption of adult behavioral functions relevant to schizophrenia Prof Joram Feldon, ETH Zurich, Laboratory of Behavioural Neurobiology, Switzerland Preferential role of NR2A subunits in NMDA receptor antagonist-induced aberrant cortical gamma oscillations: relevance to cognitive deficits in schizophrenia Bernat Kocsis, Harvard Medical School, United States Naturalistic Outcomes for Patients with Schizophrenia Treated with Olanzapine as Monotherapy or Antipsychotic Polypharmacy in Japan Yuka Tanji, Lilly Research Laboratories Japan, Eli Lilly Japan K.K., Japan Predicting Continuation of Olanzapine in the 1-year Naturalistic Treatment of Patients with Schizophrenia in Japan Wendy Ye, Lilly Research Laboratories Japan, Eli Lilly Japan K.K., Japan Season-Menopause Interaction in Affective Illness and Migraine Professor Frederick M Jacobsen, The George Washington University School of Medicine, United States Professor Lillian Comas-Diaz, The George Washington University School of Medicine, United States The metabolic effects of ziprasidone versus Olanzapine in first-episode schizophrenia: a 6-week, multicenter, randomized, flexible-dose study Dr Jian-jun Ou, Mental Health Institute of The Second Xiangya Hospital,Central South University, Changsha HUNAN, China
10:30	08Antipsychotic Drugs: Mechanisms of Action and Approaches to Treament Plenary Theatre Auditorium Chairperson Prof Brian Dean The Mental Health Research Institution Australia Advances in understanding the role of dopamine in the action of antipsychotic drugs Prof Anthony Phillips, Canadian Institues of Health Research, Canada The pharmacology of antipsychotic drugs: Old and new drug targets Prof Brian Dean, The Mental Health Research Institution, Australia Antipsychotic drug treatments: Evoling treatment statergies Prof Nicholas Keks, Monash University,Mental Health Research Institute of Victoria, Epworth Healthcare, Australia Antipsychotic drug treatments: The use of polypharmacy to get improved outcomes Dr Yeon Ho Joo, University of Ulsan College of Medicine, Korea	09Harm reduction against drug and HIV problems in Malaysia Meeting Room 304/305 Chairperson Dr Rusdi Abd. Rashid University of Malaya Malaysia History of drug use and epidemiological aspects of drug use in Malaysia Prof Mahmood Nazar Mohamed, Universiti Utara Malaysia (UUM), Malaysia Harm reduction: An update and pharmacological aspects Prof Mohamad Hussain Bin Habil Harm reduction in custodial settings in Malaysia Dr Muhammad Muhsin Ahmad Zahari, University of Malaya Medical Centre, Malaysia Spiritual enhancement drug addiction rehabilitation (SEDAR) An innovative platform for up scaling harm reduction in Malaysia Dr Rusdi Abd. Rashid, University of Malaya, Malaysia
12:00	10Lunch Conference Hall 2
12:30	11Janssen-Cilag Sponsored Symposium Plenary Theatre Auditorium Optimizing treatment outcomes in patients with schizophrenia D Andreas Schreiner, Germany
14:00	12HIV and Mental Health Plenary Theatre Auditorium Co-Chair Prof Graham Burrows AO KCSJ University of Melbourne Australia Co-Chair Prof Nur Zuraida Zainal University of Malaya Malaysia HIV and mental health Prof Ian Everall, The University of Melbourne, Australia
14:45	13Long-Term Depression of Glutamatergic Synaptic Activity: Key Roles in Cognition Plenary Theatre Auditorium Co-Chair Prof Brian Dean The Mental Health Research Institution Australia Co-Chair Dr Rusdi Abd. Rashid University of Malaya Malaysia Long-Term depression of glutamatergic synaptic activity: Key roles in cognition Prof Anthony Phillips, Canadian Institues of Health Research, Canada
15:30	14Refreshments & Posters Conference Hall 2
16:00	15Free Papers Plenary Theatre Auditorium Co-Chair A/Prof Trevor Norman University of Melbourne Australia Co-Chair A/Prof Nik Ruzyanei Nik Jaafar Malaysia The brain epigenome: Mapping brain relevant gene regulatory elements using next generation sequencing Professor Cathy L Barr, The Toronto Western Research Institute, Canada A potential imaging model 'predictive of schizophrenia', using NMDA antagonist as key psychoactive lead-compound: a multi-modal MR neuroimaging report Dr Sakthivel Sekar, Bio-Imaging Lab, University of Antwerp / Translational Research - CNS, Johnson & Johnson Pharmaceuticals Research & Development, Belgium Evidence for genetic variants in the melanocortin system predicting antipsychotic induced weight gain Prof James L Kennedy, University of Toronto, Canada	16Free Papers Meeting Room 304/305 Co-Chair Prof Nicholas Keks Monash University,Mental Health Research Institute of Victoria, Epworth Healthcare Australia Co-Chair Prof Mohd Fadzillah Abdul Razak Malaysia Antipsychotic monotherapy among outpatients with schizophrenia initiated on olanzapine or risperidone in Japan Wendy Ye, Lilly Research Laboratories Japan, Eli Lilly Japan K.K., Japan Altered resting state functional connectivity of anterior cingulate cortex in obsessive-compulsive disorder Ms Je-Yeon Yun, Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea, Korea Neural correlates of impaired response inhibition in patients with obsessive compulsive disorder before and after treatment Dr Sung Nyun Kim, 1. Department of Psychiatry, Seoul National University College of Medicine, Seoul National University Hospital, Korea
17:00

Tuesday, 21 June 2011
08:30	17Special treatment issues for women with Psychosis? Plenary Theatre Auditorium Chairperson Prof Jayashri Kulkarni Alfred Hospital and Monash University Australia Overview of special mangement issues for women with psychosis Prof Jayashri Kulkarni, Alfred Hospital and Monash University, Australia Special issues for women with bipolar affective disorder Mr Anthony de Castella, Monash Alfred Psychiatry Research Centre, The Alfred Hospital and Monash University, Australia The national register of antipsychotic medication in pregnancy (NRAMP), The first 100 women. Ms Heather Gilbert, Monash Alfred Psychiatry Research Centre, The Alfred Hospital and Monash University, Australia Hormone modulation: A novel approach to managing mental illness in women? Prof Jayashri Kulkarni, Alfred Hospital and Monash University, Australia Do women benefit more from antipsychotics than men? Prof Nur Zuraida Zainal, University of Malaya, Malaysia	18Methamphetamine dependence: from synaptic dysfuntion to pharmacogenomics Meeting Room 304/305 Chairperson Prof Gavin Reynolds Sheffield Hallam University United Kingdom Glutamatergic pharmacogenetics of methamphetamine abuse and psychosis Ms Walailuk Kerdsan, Naresuan University, Thailand The effects of methamphetamine on glutamatergic systems Dr Sutisa Nudmamud-Thanoi, Naresuan University, Thailand BDNF pharmacogenetics of methamphetamine abuse Mr Gareth Sim, University of Malaya, Malaysia Neuronal mechanisms of methamphetamine-seeking behaviour Dr Kiyofumi Yamada, Nagoya University Graduate School of Medicine, Japan
10:00	19Refreshments & Posters Conference Hall 2
10:30	20Use of neuroimaging for the effect of psychotropics Plenary Theatre Auditorium Chairperson Prof Jun Soo Kwon Seoul National University College of Medicine Korea The effects of pharmacotherapy on brain in patients with OCD Dr Jae Yeon Hwang, Seoul National University College of Medicine, Korea Near-infrared spectroscopy as a possible biomarker for predicting effect of methylphenidate in children with ADHD Ayaka Ishii, Graduate School of Medicine, University of Tokyo, Japan Structural renal changes under long-term treatment with lithium - a 3T MR study Dr Thomas J Raedler, University of Calgary, Faculty of Medicine, Department of Psychiatry, Canada Cognitive function in euthymic state of bipolar disorders: association of brain serotonin transporter and brain derived neurotrophic factor Dr Chi-Bin Yeh, Tri-Service General Hospital & National Defense Medical Center, Taiwan	21A better understanding of causes and treatment of Depression Meeting Room 304/305 Chairperson Dr Robb Stanley The Royal Society of Victoria Australia The role of inflammatory-related pathways in the pathophysiology of major depressive disorders and bipolar disorders Dr Andrew Gibbons, Mental Health Research Institute of Victoria, Australia The role of animal models in understanding depression Prof Alexandra Sulcova, Masaryk University, Czech Republic The neuropsychopharmacology of antidepressants and potential new mechanisms of action A/Prof Trevor Norman, University of Melbourne, Australia Treating depression - Current best practice Prof Isaac Schweitzer, University of Melbourne, Australia
12:00	22Lunch Conference Hall 2
12:45	23AstraZeneca Sponsored Symposium Plenary Theatre Auditorium Chairperson Dr Abdul Kadir Abu Bakar Malaysian Psychiatric Association Malaysia Bipolar Disorder: Journey from Pole to Pole Atypical Antipsychotic in the Management of Mood Disorder Roger McIntyre, Canada
14:00	24Progress in Neuroimaging Studies of High-risk subjects for Psychosis and its Relation to Clinical Psychopathology Plenary Theatre Auditorium Co-Chair Prof Brian Dean The Mental Health Research Institution Australia Co-Chair Dr Hazli Zakaria Malaysia Progress in neuroimaging studies of high-risk subjects for psychosis and its relation to clinical psychopathology Prof Jun Soo Kwon, Seoul National University College of Medicine, Korea	25Role of 5-HT1 Receptor Subtypes in Animal Models of Anxiety and Drug Dependence Meeting Room 304/305 Co-Chair A/Prof Trevor Norman University of Melbourne Australia Co-Chair A/Prof Marhani Midin Malaysia Role of 5-HT1 receptor subtypes in animal models of anxiety and drug dependence Prof Alexandra Sulcova, Masaryk University, Czech Republic
14:45	26Schizophrenia – update on prognosis, etiopathogenesis and treatment approaches Plenary Theatre Auditorium Co-Chair Prof Graham Burrows AO KCSJ University of Melbourne Australia Co-Chair Dr Abdul Kadir Abu Bakar Malaysian Psychiatric Association Malaysia Schizophrenia – update on prognosis, etiopathogenesis and treatment approaches Prof. Hans-Jürgen Möller, Ludwig-Maximilians-University München, Germany
15:30	28Refreshments & Posters Conference Hall 2
16:00	30Free Papers Plenary Theatre Auditorium Co-Chair Dr Elizabeth Scarr The University of Melbourne, Department of Psychiatry Australia Co-Chair Dr Selvasingam Ratnasingam Malaysia Psychosocial aspect of ambiguous genitalia : Two cases in central Java - Indonesia Dr Widodo Sarjana, Psychiatry Department, Faculty of Medicine, Diponegoro University, Indonesia Assessing the impact of donepezil on the performance of aged female Cynomolgus monkeys (Macaca Fascicularis) during the object- retrieval task Dr Jane S Sutcliffe, Maccine Pte Ltd, Singapore Accumbens shell AMPA receptors mediate expression of extinguished reward seeking through interactions with basolateral amygdala E Zayra Millan, University of New South Wales, Australia
17:00

Wednesday, 22 June 2011
09:00	31Pharmacogenetics of treatment response Plenary Theatre Auditorium Chairperson Prof Gavin Reynolds Sheffield Hallam University United Kingdom Influence and interaction of genetic polymorphisms in the monoaminergic system and life stress on antidepressant drug response Dr Zhi Xu, Zhongda Hospital, China Pharmacogenetics of symptom response to antipsychotic treatment Prof Gavin Reynolds, Sheffield Hallam University, United Kingdom Candidate genes for response to risperidone: from mouse to man Masashi Ikeda, Fujita Health University School of Medicine, Japan	42Bipolar Disorder: Controversies and Developments in Diagnosis and Management Meeting Room 304/305 Co-Chair Prof Nicholas Keks Monash University,Mental Health Research Institute of Victoria, Epworth Healthcare Australia Co-Chair Prof Graham Burrows AO KCSJ University of Melbourne Australia Bipolar disorder and its mangement: overview Prof Graham Burrows AO KCSJ, University of Melbourne, Australia Boundaries of bipolar disorders and adequacy of treatment Prof Nicholas Keks, Monash University,Mental Health Research Institute of Victoria, Epworth Healthcare, Australia Neurochemical changes in the CNS of people with bipolar disorders Dr Elizabeth Scarr, The University of Melbourne, Department of Psychiatry, Australia Bipolar depression: diagnostic and management issues Prof Isaac Schweitzer, University of Melbourne, Australia
10:30	40Refreshments & Posters Conference Hall 2
11:00	33Novel Mechanisms and Pharmacotherapies for Cognitive Deficits in Schizophrenia Plenary Theatre Auditorium Chairperson Dr Frank Tarazi Harvard Medical School United States From dementia praecox to schizophrenia - cognitive deficits and functional outcome in schizophrenia Dr Thomas J Raedler, University of Calgary, Faculty of Medicine, Department of Psychiatry, Canada Modelling cognitive deficit symptoms in schizophrenia: Emerging Targets Dr Jo Neill, University of Bradford, United Kingdom Histamine H3 receptor antagonists in preclinical models of cognition Dr Pascal Bonaventure, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., United States Clinical trials for cognitive deficits in schizophrenia: Boom or Bust? Dr Frank Tarazi, Harvard Medical School, United States	41Community Mental Health Services in Malaysia: Building the Capacity for Better Care Meeting Room 304/305 Chairperson Dr Abdul Kadir Abu Bakar Malaysian Psychiatric Association Malaysia Deinstitutionalization in Malaysia: a Myth or Reality? Dr Abdul Kadir Abu Bakar, Malaysian Psychiatric Association, Malaysia Home care in Malaysia: does it improve patients' care Dr Yee Chuang Cheah, Malaysia The role of cognitive remediation therapy (CRT) in psychosocial rehabilitation Dr Rafidah Bahari, Cyberjaya University & CRT project in Malaysia, Malaysia A weight management program for the severely mentally Ills A/Prof Marhani Midin, Malaysia
12:30	37Targeting the cholinergic system to treat schizophrenia: An old concept with promising new directions Plenary Theatre Auditorium Co-Chair Prof Ian Everall The University of Melbourne Australia Co-Chair Dr Muhammad Muhsin Ahmad Zahari Department of Psychological Medicine, Faculty of Medicine, University of Malaya Malaysia Targeting the cholinergic system to treat schizophrenia: An old concept with promising new directions Prof Brian Dean, The Mental Health Research Institution, Australia
13:15	39Lunch and Closing Summary Conference Hall 2
14:30